Skip to main content

Table 2 Laboratory variations in Case 2

From: Two cases of gastric cancer with elevated serum levels of KL-6

 

Before chemotherapy

After 3 cycles of 1st line chemotherapy (SOX + Tmab)

Just before 2nd line chemotherapy (PTX + Rmab)

Just before 3rd line chemotherapy (NIVO)

Just before 4th line chemotherapy (FTD/TPI)

Just before 5th line chemotherapy (XELIRI)

Months

0

2

6

13

16

18

CEA (ng/ml)

1127.8

54.0

273.1

858.5

1840.3

8552.7

KL-6 (U/ml)

2239

284

413

427

no data

1560

  1. CEA: carcinoembryonic antigen; KL-6: Krebs von den Lungen-6; SOX: chemotherapy using oxaliplatin plus S-1; Tmab: trastuzumab; PTX: paclitaxel; Rmab: ramucirumab; NIVO: nivolumab; FTD/TPI: trifluridine/tipiracil hydrochloride; XELIRI: capecitabine plus irinotecan